A development program that set a goal of starting clinical trials for knee osteoarthritis, ischemic cardiomyopathy and liver cirrhosis during 2020, and progressed in ischemic cardiomyopathy through the initiation of a Phase II investigator-initiated clinical trial and completion of dosing of the first patient.